Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck

Clinical Cancer Research

Volumn 13, Issue 14, 2007, Pages 4300-4305

  Chen, Kexin ^a   Hu, Zhibin ^a   Wang, Li E ^a   Zhang, Wei ^a   El Naggar, Adel K ^a   Sturgis, Erich M ^a   Wei, Qingyi ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; TUMOR PROTEIN 53; TUMOR PROTEIN 53 BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; DOSE RESPONSE; GENE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CANCER; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK; SQUAMOUS CELL CARCINOMA; TUMOR PROTEIN 53 BINDING PROTEIN 1 GENE; TUMOR PROTEIN 53 GENE;

AMINO ACID SUBSTITUTION; CARCINOMA, SQUAMOUS CELL; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTAGENESIS, INSERTIONAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEIN P53; VARIATION (GENETICS);

EID: 34547108823     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0469     Document Type: Article

References (39)

1. Sturgis EM, Wei Q, Spitz MR. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol 2004;31:726-33.
2. Neumann AS, Sturgis EM, Wei Q. Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog 2005;42:65-92.
3. Denissenko MFPA, Tang M, Pfeifer GP. Preferential formation of benzo [a] pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-2.
4. Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect 1996;104:435-9.
5. Cheng L, Eicher SA, Guo Z, Hong WK, Spitz MR, Wei Q. Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 1998;7:465-8.
6. Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 2002;94:393-7.
7. Wei Q, Wang LE, Sturgis EM, Mao L. Expression of nucleotide excision repair proteins in lymphocytes as a marker of susceptibility to squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev 2005;14:1961-6.
8. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92:874-97.
9. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1513-30.
10. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183:123-30.
11. Li G, Sturgis EM, Wang LE, et al. Association of a p73e xon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2004;25:1911-6.
12. Li G, Sturgis EM, Wang LE, et al. Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma. Clin Cancer Res 2004;10:3996-4002.
13. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003;116:4077-85.
14. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004;25:177-81.
15. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
16. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
17. Suspitsin EN, Buslov KG, Grigoriev MY, et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 2003;103:431-3.
18. Zhang W, Hu G, Deisseroth A. Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene 1992;117:271- 5.
19. Hildesheim A, Schiffman M, Brinton LA, et al. p53 polymorphism and risk of cervical cancer. Nature 1998;396:531-2.
20. Rosenthal AN, Ryan A, Al-Jehani RM, Storey A, Harwood CA, Jacobs IJ. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet 1998;352:871-2.
21. Keshava C, Frye BL, Wolff MS, McCanlies EC, Weston A. Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:127-30.
22. Powell BL, van Staveren IL, Roosken P, Grieu F, Berns EM, Iacopetta B. Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 2002;23:311-5.
23. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002;179:175-83.
24. Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002;94:681-90.
25. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003;18:377-85.
26. Shen H, Liu Z, Strom SS, et al. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol 2003;121:1510-4.
27. Gemignani F, Moreno V, Landi S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004;23:1954-6.
28. Adams MM, Carpenter PB. Tying the loose ends together in DNA double strand break repair with 53BP1. Cell Div 2006;1:19.
29. Iwabuchi K, Li B, Massa HF, Trask BJ, Date T, Fields S. Stimulation of TP53-mediated transcriptional activation by the TP53-binding proteins, 53BP1 and 53BP2. J Biol Chem 1998;273:26061-8.
30. Wang B, Matsuoka S, Carpenter PB, Elledge SJ. 53BP1, a mediator of the DNA damage checkpoint. Science 2002;298:1435-8.
31. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
32. Ma H, Hu Z, Zhai X, et al. Joint effects of single nucleotide polymorphisms in TP53BP1 and TP53 on breast cancer risk in a Chinese population. Carcinogenesis 2006;27:766-71.
33. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.
34. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006;25:1602-11.
35. Lehman TA, Haffty BG, Carbone CJ, et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 2000;60:1062-9.
36. Dumont P, Leu JI, Della Pietra AC III, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
37. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000;25:47-54.
38. Frank B, Hemminki K, Bermejo JL, et al. TP53-binding protein variants and breast cancer risk: a case-control study. Breast Cancer Res 2005;7:R502-5.
39. Liu Y, West SC. Distinct functions of BRCA1 and BRCA2 in double-strand break repair. Breast Cancer Res 2002;4:9-13.